ENDRA Life Sciences Inc. (NDRA) Bundle
A Brief History of ENDRA Life Sciences Inc. (NDRA)
Company Overview
ENDRA Life Sciences Inc. is a medical technology company traded on NASDAQ under the ticker NDRA. As of 2024, the company focuses on developing advanced medical imaging technologies.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $23.4 million |
| Annual Revenue | $1.2 million |
| Net Loss | $8.7 million |
| Cash and Cash Equivalents | $6.3 million |
Key Technology
ENDRA develops Thermo Acoustic Enhanced Ultrasound (TAEUS™) technology for medical imaging applications.
Product Development
- Liver Imaging Platform
- Kidney Imaging Technology
- Breast Imaging Solutions
Stock Performance
| Stock Metric | 2024 Data |
|---|---|
| Stock Price (February 2024) | $0.45 |
| 52-Week Low | $0.32 |
| 52-Week High | $0.89 |
Research and Development
Total R&D expenditure in 2023: $5.6 million
Intellectual Property
- 7 issued patents
- 4 pending patent applications
A Who Owns ENDRA Life Sciences Inc. (NDRA)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Renaissance Technologies LLC | 440,170 | 2.51% |
| Vanguard Group Inc | 386,526 | 2.20% |
| Geode Capital Management LLC | 230,579 | 1.32% |
Top Insider Owners
- Brian Norris (Chief Financial Officer): 31,250 shares
- Deepak Gupta (Chief Executive Officer): 185,000 shares
- Michael Behr (Chief Technology Officer): 42,500 shares
Public Ownership Structure
Total Outstanding Shares: 17,546,282
Institutional Ownership Percentage: 15.7%
Insider Ownership Percentage: 3.6%
Nasdaq Listing Details
Ticker Symbol: NDRA
Exchange: Nasdaq Capital Market
ENDRA Life Sciences Inc. (NDRA) Mission Statement
Company Overview
ENDRA Life Sciences Inc. (NDRA) is a medical technology company traded on NASDAQ with a focus on developing diagnostic imaging technologies.
Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $24.3 million (as of January 2024) |
| Stock Price | $1.02 (January 2024) |
| Annual Revenue | $1.2 million (2023) |
| Net Loss | $8.7 million (2023) |
Technology Focus Areas
- Thermal Ultrasound Imaging Technology
- Medical Diagnostic Solutions
- Non-Invasive Tissue Characterization
Key Technology Platform
TAEUS® Platform - proprietary thermal ultrasound technology designed for tissue characterization across multiple medical applications.
Research and Development Investments
| Year | R&D Expenditure |
|---|---|
| 2022 | $4.3 million |
| 2023 | $5.1 million |
Strategic Objectives
- Advance medical imaging technology
- Develop non-invasive diagnostic solutions
- Expand commercial applications of TAEUS® platform
Intellectual Property
15 issued and pending patents as of January 2024.
How ENDRA Life Sciences Inc. (NDRA) Works
Company Overview
ENDRA Life Sciences Inc. is a medical technology company focused on developing advanced ultrasound imaging technologies.
Key Product: Thermo Acoustic Enhanced Ultrasound (TAEUS)
ENDRA's primary technology is TAEUS, designed to improve medical imaging capabilities.
| Technology Specification | Details |
|---|---|
| Imaging Technique | Thermo Acoustic Enhanced Ultrasound |
| Patent Status | Multiple issued patents |
| Target Markets | Liver, Kidney, Breast Imaging |
Financial Performance
As of Q4 2023, ENDRA reported:
- Cash and cash equivalents: $4.1 million
- Total operating expenses: $3.2 million
- Net loss: $2.9 million
Technological Applications
TAEUS technology aims to provide enhanced medical imaging capabilities in multiple clinical domains.
| Medical Application | Potential Improvement |
|---|---|
| Liver Fat Measurement | Non-invasive quantification |
| Kidney Imaging | Improved tissue characterization |
| Breast Imaging | Enhanced diagnostic capabilities |
Research and Development
ENDRA continues investing in technological advancement and clinical validation.
- R&D expenses in 2023: $1.8 million
- Ongoing clinical studies: 3 active research programs
- Research focus areas: Liver, Kidney, Breast Imaging technologies
Stock Information
NASDAQ trading details as of January 2024:
| Stock Symbol | NDRA |
|---|---|
| Stock Price Range (2023) | $0.50 - $1.20 |
| Market Capitalization | Approximately $20 million |
How ENDRA Life Sciences Inc. (NDRA) Makes Money
Revenue Streams
ENDRA Life Sciences Inc. generates revenue through the following primary channels:
- Medical imaging technology sales
- Technology licensing
- Research and development contracts
Financial Performance
| Financial Metric | 2023 Amount |
|---|---|
| Total Revenue | $1.2 million |
| Research Grants | $750,000 |
| Product Sales | $450,000 |
Product Portfolio
Primary Product: Thermo Acoustic Enhanced Ultrasound (TAEUS) imaging technology
- Medical imaging solutions for diagnostic purposes
- Targeting healthcare and research markets
- Specialized imaging technology for various medical applications
Market Segments
| Market Segment | Revenue Contribution |
|---|---|
| Medical Research | 42% |
| Clinical Diagnostics | 35% |
| Technology Licensing | 23% |
Funding Sources
ENDRA Life Sciences secures funding through:
- Public market financing
- Research grants
- Strategic partnerships
Stock Information
| Stock Detail | 2024 Value |
|---|---|
| NASDAQ Ticker | NDRA |
| Share Price (January 2024) | $0.85 |
| Market Capitalization | $23.4 million |
ENDRA Life Sciences Inc. (NDRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.